Cover Image

Cost-Effectiveness and Budget Impact Analyses of Selective Internal Radiation Therapy versus Atezolizumab Plus Bevacizumab from a German Statutory Health Insurance Perspective

Bjoern Schwander,1 Katharina Klesper,2 Siegbert Rossol,3 Ken Herrmann,4 York Francis Zoellner5 1Department of Health Economics & Outcomes Research, AHEAD GmbH, Bietigheim-Bissingen, Baden-Württemberg, Germany; 2Department of Health Economics & Epidemiology, ECON-EPI, Meerbusch, Nordrhein-Wes...

Full description

Saved in:

Bibliographic Details
Main Authors:	Schwander B (Author), Klesper K (Author), Rossol S (Author), Herrmann K (Author), Zoellner YF (Author)
Format:	Book
Published:	Dove Medical Press, 2024-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis
by: Hongfu Cai, et al.
Published: (2024)

A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
by: Yukinobu Watanabe MD, PhD, et al.
Published: (2021)

Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis
by: Jeayeon Park, et al.
Published: (2024)

Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
by: Tae Hyun Kim, et al.
Published: (2023)

Social inequalities in the utilization of outpatient psychotherapy: analyses of registry data from German statutory health insurance
by: Jelena Epping, et al.
Published: (2017)

Analysis of second opinion programs provided by German statutory and private health insurance - a survey of statutory and private health insurers
by: Nadja Könsgen, et al.
Published: (2021)

Atezolizumab Plus Bevacizumab-induced Recalcitrant Pyoderma Gangrenosum Treated with Baricitinib: A Case Report
by: Han Seul Kim, et al.
Published: (2023)

Pustular psoriasis triggered by therapy with atezolizumab and bevacizumab
by: Mariani Magnus da Luz Andrade, et al.
Published: (2024)

Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination
by: Takahiro Niimura, et al.
Published: (2023)

Downstaging with atezolizumab-bevacizumab: a case series
by: Anand V. Kulkarni, et al.
Published: (2024)

Letter regarding "Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab"
by: Sun Hyun Bae, et al.
Published: (2023)

Favorable response of hepatocellular carcinoma with portal vein tumor thrombosis after radiotherapy combined with atezolizumab plus bevacizumab
by: Yong Tae Kim, et al.
Published: (2023)

Seroconversion after needlestick injuries - analyses of statutory accident insurance claims in Germany
by: Dulon, Madeleine, et al.
Published: (2018)

A case of successful surgical treatment for peritoneal seeding of hepatocellular carcinoma after radiotherapy and atezolizumab plus bevacizumab combination treatment
by: Yuri Cho, et al.
Published: (2023)

Cardiovascular disease prevalence in type 2 diabetes - an analysis of a large German statutory health insurance database
by: Maximilian Gabler, et al.
Published: (2021)

A case of nearly complete response in hepatocellular carcinoma with disseminated lung metastasis by combination therapy of nivolumab and ipilimumab after treatment failure of atezolizumab plus bevacizumab
by: Hyung Jun Kim, et al.
Published: (2023)

Budget impact of antimicrobial wound dressings in the treatment of venous leg ulcers in the German outpatient care sector: a budget impact analysis
by: Maria Gueltzow, et al.
Published: (2018)

Options to Extend Medicare's Trust Fund: Lessons From Japan's Statutory Health Insurance
by: Jared Lane K. Maeda PhD, MPH
Published: (2022)

Cure can be achieved by conversion to microwave ablation following atezolizumab-bevacizumab therapy in unresectable hepatocellular carcinoma
by: Rene John D. Febro, et al.
Published: (2024)

Hyperprogression in a Patient With Hepatocellular Cancer Treated With Atezolizumab and Bevacizumab: A Case Report and Review of Literature
by: Balraj Singh MD, et al.
Published: (2021)

Complete response in hepatocellular carcinoma with lymph node metastasis by combination therapy of atezolizumab and bevacizumab: a case report
by: Sang Youn Hwang, et al.
Published: (2021)

Medicare Volume Growth and Shift in Payments From Physicians to Non-Physician Practitioners Under Statutory Budget Neutrality
by: Eric W. Christensen PhD, et al.
Published: (2024)

Dental healthcare reforms in Germany and Japan: A comparison of statutory health insurance policy
by: Mayumi Nomura
Published: (2008)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
by: Qingli Cui, et al.
Published: (2022)

Concurrent transarterial radioembolization and combination atezolizumab/bevacizumab treatment of infiltrative hepatocellular carcinoma with portal vein tumor thrombosis: a case report
by: Min Kyung Park, et al.
Published: (2022)

Pharmacoeconomic analysis of atezolizumab plus nab-paclitaxel in the treatment of the advanced or metastatic triple-negative breast cancer
by: A S Kolbin, et al.
Published: (2020)

Agreement between self-reports and statutory health insurance claims data on healthcare utilization in patients with mental disorders
by: Tarcyane Barata Garcia, et al.
Published: (2023)

Sustaining Canadian marine biodiversity: Policy and statutory progress
by: Jeffrey A. Hutchings, et al.
Published: (2020)

Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial
by: Maria G. Fencer MD, et al.
Published: (2022)

Potential Benefits and Risks Resulting From the Introduction of Health Apps and Wearables Into the German Statutory Health Care System: Scoping Review
by: Heidel, Alexandra, et al.
Published: (2020)

Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis
by: Xiaoyan Liu, et al.
Published: (2022)

Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis
by: Xiaoyan Liu, et al.
Published: (2021)

Pan‐cancer population pharmacokinetics and exposure‐safety and ‐efficacy analyses of atezolizumab in patients with high tumor mutational burden
by: Colby S. Shemesh, et al.
Published: (2020)

Cost-related medication nonadherence among over-indebted individuals enrolled in statutory health insurance in Germany: a cross-sectional population study
by: Jacqueline Warth, et al.
Published: (2019)

Previous radiation patients may not be a good candidate to consider the adding bevacizumab for rescue therapy
by: Yiu-Tai Li, et al.
Published: (2023)

Cost-effectiveness and budget impact analyses of dengue vaccination in Indonesia.
by: Auliya Abdurrohim Suwantika, et al.
Published: (2021)

A case of urticarial vasculitis associated with atezolizumab
by: Jade N. Young, BS, et al.
Published: (2024)

Statutory health insurance-covered pre-exposure prophylaxis in Germany: changing trends in nationwide tenofovir disoproxil/emtricitabine prescriptions during the COVID-19 pandemic
by: Henrieke Prins, et al.
Published: (2023)

A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer
by: Suenaga M, et al.
Published: (2015)

Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy
by: Gerald HJ Mickisch, et al.
Published: (2011)